Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709585 | 0.88 | GAA (0.48) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL4401042 | 0.82 | GAA (0.48) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL10945773 | 0.82 | GAA (0.48) | GAANPC1MAPTALDH1A1CYP3A4 | |
| SCHEMBL2084949 | 0.80 | MAP3K14 (0.44) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL16047636 | 0.78 | MAPT (0.53) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL1854071 | 0.78 | GAA (0.41) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL30254383 | 0.78 | MAPT (0.53) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL17744292 | 0.78 | ERN1 (0.55) | GAANPC1MAPTALDH1A1CYP3A4 | |
| SCHEMBL27648652 | 0.75 | GAA (0.43) | GAANPC1MAPTNPSR1ALDH1A1 | |
| SCHEMBL5372123 | 0.75 | GAA (0.42) | GAANPC1ALDH1A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250237-A1 | ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2024-02-15 | — | — | US | disclosed |
| CN-117321048-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4263531-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM Due, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2022133098-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643933-B2 | Compounds useful as antibiotic tolerance inhibitors | THE GENERAL HOSPITAL CORPORATION (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014176258-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250237-A1 | ALKYLAMINE OR HETEROALKYLAMINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS3, NOS2, NOS1 | GAA 1524/4885NPC1 313/4885MAPT 2187/4885 |
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | GAA 1969/4885NPC1 656/4885MAPT 2248/4885 |
| US-20240051970-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | GAA 184/4885NPC1 859/4885MAPT 3027/4885 |
| US-20160052890-A1 | COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS | CFTR, SLC11A2, MRPS18A | GAA 162/4885NPC1 1794/4885MAPT 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.